Altogether, these results demonstrate the capacity of SVX vaccine to reshape the tumor microenvironment by strongly increasing the tumor infiltration of both CD4+ Tconv and CD8+ T cells over Treg cells therefore tipping the balance toward an efficient immune response. The gene discussed is CD8A; the disease is neoplasm.